HH018-sesutecan / Huahui Health, Genmab - LARVOL DELTA

A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models (AACR 2024) - "Sesutecan previously demonstrated promising characteristics in preclinical studies with multiple targets and conferred an encouraging benefit:risk profile in the clinic with a FRα-directed ADC (rinatabart sesutecan). In summary, our studies demonstrate that the pH-dependent CD98-directed HH018- sesutecan exerts wide-ranging and potent anti-tumor efficacy, as well as favorable PK and safety profiles in preclinical models. HH018-sesutecan is a promising agent for further development in a broad range of CD98-expressing tumors."

Late-breaking abstract • PK/PD data • Preclinical • Tumor microenvironment • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hypopharyngeal Cancer • Lymphoma • Oncology • Oral Cancer • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • FOLR1 • SLC3A2 • SLC7A5

ProfoundBio to Present Data on Multiple Preclinical Programs From Its Antibody-Drug Conjugate Pipeline at the American Association for Cancer Research Annual Meeting 2024 (PRNewswire) - "ProfoundBio...announced its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024....ProfoundBio will showcase its innovative ADC programs through an oral presentation on its EGFR- and cMET-dual targeting ADC PRO1286, a poster presentation detailing preclinical data of a SLITRK6-directed ADC PRO1106, and a late-breaking poster presentation on a CD98-directed ADC developed in partnership with Huahui Health, a clinical-stage biotechnology company."

Late-breaking abstract • Preclinical • Oncology

Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting (PRNewswire) - "Huahui Health Ltd...announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microenvironment targeting CD98-directed ADC, at the American Association for Cancer Research (AACR) Annual Meeting 2024....The AACR meeting will be held April 5–10, 2024, in San Diego, California."

Preclinical • Oncology